Company Overview
JANUX THERAPEUTICS, INC.
JANXRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
—M
2025 FY
Net Income
-114M
2025 FY
Shares Outstanding
62M
2025 FY
EPS
-1.83USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1817713
Exchange
Nasdaq
Location
US